Cornerstone Capital Inc. Sells 64,500 Shares of Viking Therapeutics, Inc. $VKTX

Cornerstone Capital Inc. cut its position in Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by 75.5% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 20,970 shares of the biotechnology company’s stock after selling 64,500 shares during the period. Cornerstone Capital Inc.’s holdings in Viking Therapeutics were worth $684,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Ameritas Advisory Services LLC acquired a new position in shares of Viking Therapeutics in the 2nd quarter valued at $32,000. Ballast Advisors LLC acquired a new stake in Viking Therapeutics during the 1st quarter worth $33,000. Root Financial Partners LLC acquired a new stake in Viking Therapeutics during the 3rd quarter worth $34,000. Allworth Financial LP acquired a new stake in Viking Therapeutics during the 2nd quarter worth $53,000. Finally, Northwestern Mutual Wealth Management Co. bought a new position in Viking Therapeutics during the second quarter worth about $56,000. 76.03% of the stock is owned by institutional investors.

Analyst Ratings Changes

VKTX has been the topic of several recent analyst reports. Morgan Stanley reiterated an “overweight” rating on shares of Viking Therapeutics in a report on Tuesday, September 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Viking Therapeutics in a report on Thursday, October 15th. Canaccord Genuity Group raised their price target on Viking Therapeutics from $106.00 to $118.00 and gave the stock a “buy” rating in a research report on Friday, October 30th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $34.00 price target on shares of Viking Therapeutics in a research report on Thursday, October 29th. Finally, Oppenheimer set a $120.00 price objective on Viking Therapeutics in a report on Tuesday, September 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $93.36.

Get Our Latest Report on VKTX

Viking Therapeutics Stock Down 8.3%

Viking Therapeutics stock opened at $26.80 on Tuesday. The company has a 50 day moving average of $29.17 and a 200-day moving average of $32.15. The company has a quick ratio of 7.27, a current ratio of 7.27 and a debt-to-equity ratio of 0.43. Viking Therapeutics, Inc. has a twelve month low of $23.82 and a twelve month high of $43.10. The stock has a market capitalization of $3.42 billion, a PE ratio of -4.96 and a beta of 0.79.

Viking Therapeutics (NASDAQ:VKTX – Get Free Report) last issued its quarterly earnings data on Wednesday, October 28th. The biotechnology company reported ($1.55) EPS for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.49). During the same period last year, the business posted ($0.81) EPS. On average, equities research analysts anticipate that Viking Therapeutics, Inc. will post -5.26 EPS for the current fiscal year.

About Viking Therapeutics

(Free Report)

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California. Founded in 2012, it develops medicines for metabolic and endocrine disorders and does not have commercially marketed products. The company’s pipeline includes VK2735, an investigational drug that targets the GLP-1 and GIP receptors and is being developed for obesity, and VK2809, a thyroid hormone receptor beta agonist being studied for metabolic and liver conditions. Viking is also developing VK0214 for X-linked adrenoleukodystrophy, a rare genetic disorder.

Further Reading

Institutional Ownership by Quarter for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.